Thomas Gremmel

List of Publications by Year
in descending order

108	2,294	185998 28	253896 43
papers	citations	h-index	g-index

112	112	112	3075
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Platelet Physiology. Seminars in Thrombosis and Hemostasis, 2016, 42, 191-204.	1.5	233
2	Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thrombosis and Haemostasis, 2009, 101, 333-339.	1.8	114
3	Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition. Heart, 2010, 96, 186-189.	1.2	106
4	Chronic kidney disease is associated with increased platelet activation and poor response to antiplatelet therapy. Nephrology Dialysis Transplantation, 2013, 28, 2116-2122.	0.4	104
5	Enzymatic lipid oxidation by eosinophils propagates coagulation, hemostasis, and thrombotic disease. Journal of Experimental Medicine, 2017, 214, 2121-2138.	4.2	78
6	Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel. Journal of Thrombosis and Haemostasis, 2010, 8, 37-42.	1.9	61
7	Smoking promotes clopidogrel-mediated platelet inhibition in patients receiving dual antiplatelet therapy. Thrombosis Research, 2009, 124, 588-591.	0.8	56
8	Synergistic Inhibition of Both P2Y ₁ and P2Y ₁₂ Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 501-509.	1.1	49
9	Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 171-180.	1.4	46
10	The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent. Thrombosis Research, 2011, 128, 352-357.	0.8	45
11	Soluble p-selectin, D-dimer, and high-sensitivity C-reactive protein after acute deep vein thrombosis of the lower limb. Journal of Vascular Surgery, 2011, 54, 48S-55S.	0.6	44
12	Comparison of Aggregometry with Flow Cytometry for the Assessment of AgonistsÂ´-Induced Platelet Reactivity in Patients on Dual Antiplatelet Therapy. PLoS ONE, 2015, 10, e0129666.	1.1	44
13	Novel aspects of antiplatelet therapy in cardiovascular disease. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 439-449.	1.0	41
14	Comparison of methods to evaluate aspirin-mediated platelet inhibition after percutaneous intervention with stent implantation. Platelets, 2011, 22, 188-195.	1.1	36
15	Obesity is associated with poor response to clopidogrel and an increased susceptibility to protease activated receptor-1 mediated platelet activation. Translational Research, 2013, 161, 421-429.	2.2	35
16	Platelet-specific markers are associated with monocyte-platelet aggregate formation and thrombin generation potential in advanced atherosclerosis. Thrombosis and Haemostasis, 2016, 115, 615-621.	1.8	35
17	New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors. European Journal of Medicinal Chemistry, 2016, 107, 204-218.	2.6	35
18	In vivo and protease-activated receptor-1-mediated platelet activation but not response to antiplatelet therapy predict two-year outcomes after peripheral angioplasty with stent implantation. Thrombosis and Haemostasis, 2014, 111, 474-482.	1.8	34

#	Article	IF	Citations
19	Impact of variables of the P-selectin â€“ P-selectin glycoprotein ligand-1 axis on leukocyte-platelet interactions in cardiovascular disease. Thrombosis and Haemostasis, 2015, 113, 806-812.	1.8	34
20	Sublingual functional capillary rarefaction in chronic heart failure. European Journal of Clinical Investigation, 2018, 48, e12869.	1.7	34
21	Clinical, genetic and confounding factors determine the dynamics of the in vitro response/non response to clopidogrel. Thrombosis and Haemostasis, 2011, 106, 211-218.	1.8	33
22	The Influence of Proton Pump Inhibitors on the Antiplatelet Potency of Clopidogrel Evaluated by 5 Different Platelet Function Tests. Journal of Cardiovascular Pharmacology, 2010, 56, 532-539.	0.8	32
23	Is TRAP-6 suitable as a positive control for platelet reactivity when assessing response to clopidogrel?. Platelets, 2010, 21, 515-521.	1.1	31
24	Response to antiplatelet therapy and platelet reactivity to thrombin receptor activating peptide-6 in cardiovascular interventions: Differences between peripheral and coronary angioplasty. Atherosclerosis, 2014, 232, 119-124.	0.4	31
25	Circulating microRNAs identify patients at increased risk of in-stent restenosis after peripheral angioplasty with stent implantation. Atherosclerosis, 2018, 269, 197-203.	0.4	31
26	Bleeding and ischaemic outcomes in patients treated with dual or triple antithrombotic therapy: systematic review and meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 226-236.	1.4	31
27	Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thrombosis and Haemostasis, 2009, 101, 333-9.	1.8	31
28	Sex differences of leukocyteâ€“platelet interactions and on-treatment platelet reactivity in patients with atherosclerosis. Atherosclerosis, 2014, 237, 692-695.	0.4	30
29	The formation of monocyteâ€“platelet aggregates is independent of on-treatment residual agonistsâ€™-inducible platelet reactivity. Atherosclerosis, 2009, 207, 608-613.	0.4	29
30	Residual platelet activation through protease-activated receptors (PAR)-1 and â€4 in patients on P2Y12 inhibitors. International Journal of Cardiology, 2013, 168, 403-406.	0.8	28
31	Novel Antiplatelet Agents in Cardiovascular Disease. Journal of Cardiovascular Pharmacology and Therapeutics, 2020, 25, 191-200.	1.0	28
32	Prasugrel Reduces Agonistsâ€² Inducible Platelet Activation and Leukocyteâ€“Platelet Interaction more efficiently than Clopidogrel. Cardiovascular Therapeutics, 2013, 31, e40-5.	1.1	27
33	Differential impact of cytochrome 2C9 allelic variants on clopidogrel-mediated platelet inhibition determined by five different platelet function tests. International Journal of Cardiology, 2013, 166, 126-131.	0.8	27
34	Glycocalyx as Possible Limiting Factor in COVID-19. Frontiers in Immunology, 2021, 12, 607306.	2.2	27
35	Influence of cytochrome 2C19 allelic variants on on-treatment platelet reactivity evaluated by five different platelet function tests. Thrombosis Research, 2012, 129, 616-622.	0.8	24
36	Functional capillary impairment in patients with ventricular assist devices. Scientific Reports, 2019, 9, 5909.	1.6	21

#	Article	IF	Citations
37	Ticagrelor Inhibits Toll-Like and Protease-Activated Receptor Mediated Platelet Activation in Acute Coronary Syndromes. Cardiovascular Drugs and Therapy, 2020, 34, 53-63.	1.3	20
38	Hereditary amyloidosis caused by R554L fibrinogen AÎ±-chain mutation in a Spanish family and review of the literature. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 72-79.	1.4	19
39	Differential Impact of Inflammation on Six Laboratory Assays Measuring Residual Arachidonic Acid-Inducible Platelet Reactivity During Dual Antiplatelet Therapy. Journal of Atherosclerosis and Thrombosis, 2013, 20, 630-645.	0.9	19
40	Residual thrombin generation potential is inversely linked to the occurrence of atherothrombotic events in patients with peripheral arterial disease. European Journal of Clinical Investigation, 2014, 44, 319-324.	1.7	18
41	Proteaseâ€activated receptorâ€mediated platelet aggregation in acute coronary syndrome patients on potent P2Y12 inhibitors. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 383-390.	1.0	18
42	Sublingual microvasculature in diabetic patients. Microvascular Research, 2020, 129, 103971.	1.1	17
43	Platelet-monocyte cross talk and tissue factor expression in stable angina vs. unstable angina/non ST-elevation myocardial infarction. Platelets, 2011, 22, 530-536.	1.1	16
44	Decreased platelet inhibition by P2Y12 receptor blockers in anaemia. European Journal of Clinical Investigation, 2018, 48, e12861.	1.7	16
45	A high maintenance dose increases the inhibitory response to clopidogrel in patients with high on-treatment residual platelet reactivity. International Journal of Cardiology, 2012, 160, 109-113.	0.8	15
46	Preserved thrombinâ€inducible platelet activation in thienopyridineâ€treated patients. European Journal of Clinical Investigation, 2013, 43, 689-697.	1.7	15
47	Microparticle-associated tissue factor activity in patients with acute unprovoked deep vein thrombosis and during the course of one year. Thrombosis Research, 2014, 134, 1093-1096.	0.8	15
48	Disaggregation Following Agonist-Induced Platelet Activation in Patients on Dual Antiplatelet Therapy. Journal of Cardiovascular Translational Research, 2017, 10, 359-367.	1.1	15
49	Platelet-to-lymphocyte and Neutrophil-to-lymphocyte Ratios Predict Target Vessel Restenosis after Infrainguinal Angioplasty with Stent Implantation. Journal of Clinical Medicine, 2020, 9, 1729.	1.0	15
50	Surrogate Markers of Neutrophil Extracellular Trap Formation are Associated with Ischemic Outcomes and Platelet Activation after Peripheral Angioplasty and Stenting. Journal of Clinical Medicine, 2020, 9, 304.	1.0	15
51	Interleukin-6 and Asymmetric Dimethylarginine Are Associated with Platelet Activation after Percutaneous Angioplasty with Stent Implantation. PLoS ONE, 2015, 10, e0122586.	1.1	14
52	Oral antiplatelet agents in cardiovascular disease. Vasa - European Journal of Vascular Medicine, 2019, 48, 291-302.	0.6	14
53	Calciumâ€Channel Blockers Attenuate the Antiplatelet Effect of Clopidogrel. Cardiovascular Therapeutics, 2015, 33, 264-269.	1.1	13
54	Using extracellular calcium concentration and electric pulse conditions to tune platelet-rich plasma growth factor release and clotting. Medical Hypotheses, 2019, 125, 100-105.	0.8	13

#	Article	IF	Citations
55	Plasma Levels of snoRNAs are Associated with Platelet Activation in Patients with Peripheral Artery Disease. International Journal of Molecular Sciences, 2019, 20, 5975.	1.8	13
56	Î±-Hydroxybutyrate dehydrogenase is associated with atherothrombotic events following infrainguinal angioplasty and stenting. Scientific Reports, 2019, 9, 18200.	1.6	12
57	High levels of platelet-monocyte aggregates after valve replacement for aortic stenosis: Relation to soluble P-selectin and P-selectin glycoprotein ligand-1 genes. Thrombosis Research, 2012, 129, 453-458.	0.8	11
58	Response to antiplatelet therapy is independent of endogenous thrombin generation potential. Thrombosis Research, 2013, 132, e24-e30.	0.8	11
59	The Antiplatelet Effect of Clopidogrel Decreases With Patient Age. Angiology, 2016, 67, 902-908.	0.8	11
60	Oral antiplatelet therapy: impact for transfusion medicine. Vox Sanguinis, 2017, 112, 511-517.	0.7	11
61	Soluble CD40 Ligand in Aspirin-Treated Patients Undergoing Cardiac Catheterization. PLoS ONE, 2015, 10, e0134599.	1.1	11
62	The Thr715Pro variant impairs terminal glycosylation of P-selectin. Thrombosis and Haemostasis, 2012, 108, 963-972.	1.8	10
63	Underlying mechanism and specific prevention of hemolysis-induced platelet activation. Platelets, 2017, 28, 555-559.	1.1	10
64	Impact of diabetes on platelet activation in different manifestations of atherosclerosis. Swiss Medical Weekly, 2013, 143, w13800.	0.8	10
65	Serum Cholinesterase Levels Are Associated With 2-Year Ischemic Outcomes After Angioplasty and Stenting for Peripheral Artery Disease. Journal of Endovascular Therapy, 2016, 23, 738-743.	0.8	9
66	Tunable activation of therapeutic platelet-rich plasma by pulse electric field: Differential effects on clot formation, growth factor release, and platelet morphology. PLoS ONE, 2018, 13, e0203557.	1.1	9
67	Impaired glucose metabolism is associated with increased thrombin generation potential in patients undergoing angioplasty and stenting. Cardiovascular Diabetology, 2018, 17, 131.	2.7	9
68	Response to aspirin therapy in patients with myeloproliferative neoplasms depends on the platelet count. Translational Research, 2018, 200, 35-42.	2.2	9
69	Î²â€blockers are associated with decreased leucocyteâ€“platelet aggregate formation and lower residual platelet reactivity to adenosine diphosphate after angioplasty and stenting. European Journal of Clinical Investigation, 2016, 46, 1041-1047.	1.7	7
70	Calpain-1 regulates platelet function in a humanized mouse model of sickle cell disease. Thrombosis Research, 2017, 160, 58-65.	0.8	7
71	Circulating MicroRNAs and Monocyteâ€“Platelet Aggregate Formation in Acute Coronary Syndrome. Thrombosis and Haemostasis, 2021, 121, 913-922.	1.8	7
72	Microvascular rarefaction in patients with cerebrovascular events. Microvascular Research, 2022, 140, 104300.	1.1	7

#	Article	IF	Citations
73	Human neutrophil Î±-defensins are associated with adenosine diphosphate-inducible neutrophil-platelet aggregate formation and response to clopidogrel in patients with atherosclerosis. Translational Research, 2014, 164, 202-208.	2.2	6
74	In Vivo and protease-activated receptor-1-mediated platelet activation in patients presenting for cardiac catheterization. Platelets, 2016, 27, 308-316.	1.1	6
75	Low Levels of High-Density Lipoprotein Cholesterol Are Linked to Impaired Clopidogrel-Mediated Platelet Inhibition. Angiology, 2018, 69, 786-794.	0.8	6
76	Platelet activation and aggregation in different centrifugal-flow left ventricular assist devices. Platelets, 2022, 33, 249-256.	1.1	6
77	The P-selectin gene Pro715 allele and low levels of soluble P-selectin are associated with reduced P2Y12 adenosine diphosphate receptor reactivity in clopidogrel-treated patients. Atherosclerosis, 2011, 217, 135-138.	0.4	5
78	Association of Thrombin Generation Potential with Platelet PAR-1 Regulation and P-Selectin Expression in Patients on Dual Antiplatelet Therapy. Journal of Cardiovascular Translational Research, 2014, 7, 126-132.	1.1	5
79	Acute Limb Ischemia after Intake of the Phenylethylamine Derivate NBOMe. International Journal of Environmental Research and Public Health, 2019, 16, 5071.	1.2	5
80	Residual platelet reactivity in low-dose aspirin-treated patients with class 1 obesity. Vascular Pharmacology, 2021, 136, 106819.	1.0	5
81	Peripheral versus central venous blood sampling does not influence the assessment of platelet activation in cirrhosis. Platelets, 2022, 33, 879-886.	1.1	5
82	Proteaseâ€activated receptorâ€mediated platelet aggregation in patients with type 2 diabetes on potent <scp>P2Y</scp>₁₂ inhibitors. Diabetic Medicine, 2022, 39, e14868.	1.2	5
83	Gross proteinuria and subacute renal failure after coronary angiography â€“ a case report of cholesterol crystal embolization. Wiener Klinische Wochenschrift, 2010, 122, 251-254.	1.0	4
84	Liver Function is Associated With Response to Clopidogrel Therapy in Patients Undergoing Angioplasty and Stenting. Angiology, 2016, 67, 835-839.	0.8	4
85	Non-vitaminÂK antagonist oral anticoagulants in patients with an increased risk of bleeding. Wiener Klinische Wochenschrift, 2018, 130, 722-734.	1.0	4
86	Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1. European Heart Journal, 2019, 40, 3010-3012.	1.0	4
87	Comparison of Light Transmission Aggregometry With Impedance Aggregometry in Patients on Potent P2Y12 Inhibitors. Journal of Cardiovascular Pharmacology and Therapeutics, 2021, 26, 260-268.	1.0	4
88	Sex-specific platelet activation through protease-activated receptor-1 in patients undergoing cardiac catheterization. Atherosclerosis, 2021, 339, 12-19.	0.4	4
89	Growth Differentiation Factor-15 Correlates Inversely with Protease-Activated Receptor-1-Mediated Platelet Reactivity in Patients with Left Ventricular Assist Devices. Pharmaceuticals, 2022, 15, 484.	1.7	4
90	Frequency of heparin/platelet factor 4-dependent platelet antibodies in patients undergoing angioplasty and stenting for cardiovascular disease and their role for on-clopidogrel platelet reactivity. Clinical Research in Cardiology, 2012, 101, 445-452.	1.5	3

#	Article	IF	Citations
91	Plasminogen activator inhibitor-1 4G/5G genotype and residual venous occlusion following acute unprovoked deep vein thrombosis of the lower limb: A prospective cohort study. Thrombosis Research, 2017, 153, 71-75.	0.8	3
92	Association of Soluble Suppression of Tumorigenesis 2 (sST2) With Platelet Activation, Monocyte Tissue Factor and Ischemic Outcomes Following Angioplasty and Stenting. Frontiers in Cardiovascular Medicine, 2020, 7, 605669.	1.1	3
93	Mean Corpuscular Volume Predicts Adverse Outcomes Following Peripheral Angioplasty With Stenting and Is Associated With On-Treatment Platelet Reactivity. Angiology, 2021, 72, 16-23.	0.8	3
94	Activation of platelet-rich plasma by pulse electric fields: Voltage, pulse width and calcium concentration can be used to control and tune the release of growth factors, serotonin and hemoglobin. PLoS ONE, 2021, 16, e0249209.	1.1	3
95	Research update for articles published in <scp>EJCI</scp> in 2014. European Journal of Clinical Investigation, 2016, 46, 880-894.	1.7	2
96	Decreased Platelet Inhibition by Thienopyridines in Hyperuricemia. Cardiovascular Drugs and Therapy, 2021, 35, 51-60.	1.3	2
97	Platelet-to-Lymphocyte Ratio as Marker of Platelet Activation in Patients on Potent P2Y₁₂ Inhibitors. Journal of Cardiovascular Pharmacology and Therapeutics, 2022, 27, 107424842210965.	1.0	2
98	Research update for articles published in <scp>EJCI</scp> in 2013. European Journal of Clinical Investigation, 2015, 45, 1005-1016.	1.7	1
99	Critical appraisal of the AUGUSTUS trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 187-188.	1.4	1
100	Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Coronary Syndrome: Implications for Platelet Reactivity?. Cardiovascular Drugs and Therapy, 2021, 35, 1183-1190.	1.3	1
101	Recurrent Circumflex Artery Embolization Due to a Free-Floating Fibroelastoma at the Aortic Valve. Annals of Thoracic Surgery, 2011, 91, 1626.	0.7	0
102	The trapped mitral regurgitation. European Heart Journal Cardiovascular Imaging, 2017, 18, 943-943.	0.5	0
103	Bone cement in the right heart. European Heart Journal Cardiovascular Imaging, 2018, 19, 825-825.	0.5	0
104	Research update for articles published in <scp>EJCI</scp> in 2016. European Journal of Clinical Investigation, 2018, 48, e13016.	1.7	0
105	Laboratory Monitoring of Antiplatelet Therapy. , 2019, , 653-682.		0
106	P6396LDL cholesterol promotes neutrophil extracellular trap formation. European Heart Journal, 2019, 40, .	1.0	0
107	Antithrombotic treatment strategies after PCI. Lancet, The, 2020, 395, 865.	6.3	0
108	Hypoxia Reoxygenation Treatment Induces Platelet Hyperactivity and Relieves Calpain-1-Mediated Inhibition of Platelet Aggregation in a Mouse Model of Severe Sickle Cell Disease. Blood, 2015, 126, 413-413.	0.6	0